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Abstract
Nephrolithiasis is a common nephrologic disorder with complex etiology. To identify the genetic factor(s) for nephrolithiasis,
we conducted a three-stage genome-wide association study (GWAS) using a total of 5,892 nephrolithiasis cases and 17,809
controls of Japanese origin. Here we found three novel loci for nephrolithiasis: RGS14-SLC34A1-PFN3-F12 on 5q35.3
(rs11746443; P=8.51610
212, odds ratio (OR)=1.19), INMT-FAM188B-AQP1 on 7p14.3 (rs1000597; P=2.16610
214, OR=1.22),
and DGKH on 13q14.1 (rs4142110; P=4.62610
29, OR=1.14). Subsequent analyses in 21,842 Japanese subjects revealed the
association of SNP rs11746443 with the reduction of estimated glomerular filtration rate (eGFR) (P=6.54610
28), suggesting
a crucial role for this variation in renal function. Our findings elucidated the significance of genetic variations for the
pathogenesis of nephrolithiasis.
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Introduction
Nephrolithiasis, also called kidney stone, is a common disorder
which causes severe acute back pain and sometimes leads to severe
complications such as pyelonephritis or acute renal failure. Life-
time prevalence of nephrolithiasis is estimated to be 4–9% in
Japan [1], and nearly 60% of patients reveal recurrence within 10
years after their initial treatment [2]. Most of kidney stones are
composed of calcium oxalate or calcium phosphate crystals [3].
Hypercalciuria, urinary tract infection, and alkaline urine are
considered to cause urinary supersaturation and subsequently
induce the formation of calcium stone. Westernized diet, obesity,
and dehydration were also indicated their association with ne-
phrolithiasis [4,5]. In addition, a family history was reported to
increase the disease risk (2.57 times higher) in males [6], and
the concordance rate of the disease in monozygotic twins was
significantly higher than that in dizygotic twins (32.4% vs. 17.3%)
[7], indicating a pivotal role of genetic factors in its etiology. In
2009, a genome wide association study (GWAS) in Caucasian
revealed a significant association of the CLDN14 gene with
nephrolithiasis and bone mineral density [8]. To investigate the
genetic factors that are associated with the risk of nephrolithiasis in
Japanese population, we conducted three-stage GWAS (Figure S1
and Table S1).
Results/Discussion
In GWAS, we genotyped 1,000 Japanese patients with
nephrolithiasisand7,936 non-nephrolithiasis controlsusing Human
Omni Express BeadChip. Patients with struvite, cystine, ammoni-
um acid urate, and uric acid stone, or secondary nephrolithiasis
caused by drugs, hyperparathyroidism, or kidney deformity were
excluded from our analysis, since their underlying pathology is
different from that of calcium nephrolithiasis. After standard
quality-control filtering (call rate $0.99 in cases and controls,
Hardy-Weinberg P$1610
26 in controls), we conducted principal
component analysis and found that all subjects were of Asian
ancestry (Figure S2). We evaluated the association of SNPs with
nephrolithiasis by Cochran-Armitage trend test. As a result, the
genomic inflation factor was calculated to be 1.123 (Figure S3). To
adjust population stratification, we used two methods, logistic
regression analysis using top principle components as covariate and
the association analysis using 904 cases and 7,471 controls
belonging to the Hondo cluster, the major cluster of Japanese
population [9]. As a result, the genomic inflation factors for these
analyses were improved to be 1.054 (adjustment by PC1 and PC2)
and 1.042 (Hondo cluster), respectively (Figure S4a, S4b). Finally,
we decide to use only Hondo cluster samples in GWAS to minimize
likelihood of false positive associations. Although no SNP achieved
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28), we selected top 100
SNPs (P#7.85610
25) showing the smallest P-value for further
association analysis (Figure S4c and Table S2).
We selected 64 SNPs by linkage disequilibrium analysis with
the criteria of pairwise r
2 of $0.8 from the top 100 SNPs in 37
genomic regions and analyzed them using 2,783 Japanese ne-
phrolithiasis cases and 5,251 controls. Fifty nine SNPs among 64
SNPs passed the same quality-control filtering as GWAS and were
subjected to association analysis with nephrolithiasis by Cochran-
Armitage trend test. We found 11 SNPs in five loci to be sig-
nificantly associated with nephrolithiasis after Bonferroni correction
(P,0.05/59=8.47610
24, Table S3). A meta-analysis of GWAS
and stage 2 revealed that seven SNPs cleared the genome wide
significant threshold (P,5610
28) (Table S4). Therefore, we
considered stage 3 as a replication analysis for these seven SNPs.
Subsequently, we genotyped 11 SNPs in the additional cohort
consisting of 2,109 nephrolithiasis cases and 4,622 controls. We
excluded SNP rs10866504 from further analysis due to departure
from Hardy-Weinberg equilibrium (HWE) in control samples. Five
SNPs amongtenclearedthe significantthreshold (P,0.005)instage
3 (TableS5a).Ameta-analysiswitha fixed-effectsmodelrevealedall
five SNPs indicated the significant association (P,5610
28) without
heterogeneity between three studies (Table 1). SNP rs3765623 also
exhibited trend of association in stage 3 with p-value of 0.0371,
however this SNP did not clear the genome wide significant
threshold in the meta-analysis (P=1.28610
27) (Table S5b).
AlthoughSNPrs7981733 andrs1170155 alsoclearedthesignificant
threshold in the meta-analysis (P=1.43610
28 and 3.89610
29,
respectively), these two SNPs did not indicate significant association
in stage 3 (P=0.0705 and 0.132, respectively) and exhibited
heterogeneity between three studies (Table S5b). Therefore, further
analysis is necessary to elucidate the role of these SNPs in the
pathogenesis of nephrolithiasis. After all, we found three novel
loci for nephrolithiasis: RGS14-SLC34A1-PFN3-F12 on 5q35.3
(rs11746443; P=8.51610
212, odds ratio (OR)=1.19), INMT-
FAM188B-AQP1 on 7p14.3 (rs1000597; P=2.16610
214,O R =
1.22), and DGKH on 13q14.1 (rs4142110; P=4.62610
29,
OR=1.14).
Multiple SNPs in 5q35 and 7p14 regions indicated the
significant association with nephrolithiasis. SNP rs11746443 in
5q35 was in strong linkage disequilibrium with rs12654812
(D’=0.992 and r
2=0.600), while SNP rs1000597 in 7q14 was
also in high linkage disequilibrium with rs12669187 (D’=0.87
and r
2=0.64). To further evaluate the effects of these variations,
we conducted the conditional analyses. As a result, all four SNPs
remained to be significantly associated with nephrolithiasis (P,
0.05, Table S6). These findings suggested that haplotypes carrying
these SNPs would be associated with the risk of nephrolithiasis.
Then we selected the most significant SNPs from each of the
three genomic region and examined the association of these SNPs
with several clinical parameters [10,11] which were shown to
increase the risk of nephrolithiasis using up to a total of 27,323
independent Japanese samples [12]. We found no significant
association of these SNPs with serum calcium, phosphorous, urate,
and body mass index (BMI), but the risk allele of rs11746443
was significantly associated with the reduction of estimated
glomerular filtration rate (eGFR) (P=6.54610
28, Table 2). We
also conducted subgroup analyses stratified by gender, age, and
BMI status, and found that SNP rs11746443 exhibited stronger
effect among individuals with higher BMI (.24, OR of 1.27) than
those with lower BMI (,24, OR of 1.14). However this difference
(P=0.04) was not statistically significant after the multiple testing
correction (Figure S5).
To further characterize these loci, we conducted imputation
analyses of each genomic region in the GWAS samples (904 cases
and 7,471 controls) using data from HAPMAP phase II (JPT). The
regional association plots revealed that all modestly-associated
SNPs are confined within an RGS14-SLC34A1-PFN3-F12 region
on chromosome 5q35.3, an INMT-FAM188B-AQP1 region on
7p14.3, and a DGKH region on 13q14.1, respectively (Figure 1a,
1b, 1c and Figure S6a, S6b, S6c). The result of imputation analysis
revealed that a SNP rs3812036 in intron 4 of SLC34A1 showed the
strongest association with P-value of 1.48610
25 among SNPs
within the RGS14-SLC34A1-PFN3-F12 region (Figure S6a and
Table S7). SLC34A1 encodes NPT2, a member of the type II
sodium-phosphate co-transporter family which was highly ex-
pressed in kidney (Figure S7a). Mutations of SLC34A1 were known
to cause hypophosphatemic nephrolithiasis and osteoporosis in
human [13] and severe renal phosphate wasting and hypercalci-
uria in mice [14]. In addition, a GWAS reported previously
revealed the association of variations on SLC34A1 locus with
kidney function [15] and serum phosphorus concentration [16].
Although we did not find a significant association with serum
phosphorus in Japanese population, the risk allele of SNP
rs11746443 was associated with the reduction of eGFR, a marker
of renal function, suggesting that variations in this region could
regulate renal function and subsequently affect the risk of
nephrolithiasis.
The most significantly-associated SNP rs1000597 on chromo-
some 7p14.3 is located at 5.2 kb downstream of the FAM188B
gene and at 14.2 kb upstream of the AQP1 gene which encodes
aquaporin-1 (Figure S8a). The result of imputation analysis
revealed that more than ten strongly associated SNPs were
clustered around FAM188B region (Table S8a), however the role
of FAM188B in the pathogenesis of nephrolithiasis was not
reported so far. Aquaporin-1 was abundantly expressed in kidney
(Figure S7b) and function as a water channel [17]. Moreover, Aqp1
null mice exhibited reduced osmotic water permeability in
membrane of kidney proximal tube and became severely de-
hydrated after water deprivation, indicating the important role for
aquaporin-1 in the urinary concentrating mechanism [17].
Interestingly, rs1000597 is also located within intron 6 of
ENST00000434909, which is predicted to encode a 329-amino-
acid protein consisting of the carboxy-terminal portion of
FAM188B (residue 655–742) and the carboxy-terminal portion
Author Summary
Although nephrolithiasis is one of the most common
nephro-urological disorders with high prevalence (4%–9%)
and extremely high recurrence rate (60% within ten years),
little is known about the role of common variations in its
pathogenesis. Through a GWAS using a total of 5,892 cases
and 17,809 controls, we identified three novel nephroli-
thiasis loci: rs11746443, rs1000597, and rs4142110
(P,1610
28). The top two significant SNPs, rs11746443
and rs1000597, are located upstream of the SLC34A1 and
the AQP1 genes that play important roles in kidney
function and the urine-concentration process, respectively.
We also found that SNP rs11746443 is associated with the
reduction of estimated glomerular filtration rate (eGFR),
indicating the role of this variation in kidney function.
Although nephrolithiasis is considered as one of the
lifestyle-related diseases, the results of dietary intervention
studies to reduce the recurrence incidence have been
unsuccessful. Our findings could contribute to a better
understanding of the pathogenesis of nephrolithiasis and
lead to the development of new therapeutics.
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physiological roles of ENST00000434909 have not been charac-
terized yet, quantitative real-time PCR analysis revealed that this
gene was preferentially expressed in kidney (Figure S8c). Taken
together, SNP rs1000597 is likely to be associated with regulation
of AQP1 and/or ENST00000434909 expression, and subsequently
affect the urine-concentration process and increase the risk of
nephrolithiasis.
SNP rs4142110 on DGKH was also indicated strong association
by the meta-analysis of three studies. DGKH was expressed in brain
(Figure S7c) and possibly elated to psychiatric disorders such as
bipolar and major depressive disease [18,19], but its involvement
in renal function or calcium homeostasis has not been reported.
Although several SNPs on chromosome 13p14.1 including
rs7981733 showed stronger association with nephrolithiasis than
rs4142110 in GWAS and imputation analysis (Table S8b), none of
these associated SNPs alter amino acid sequence. Therefore,
further association and functional analyses would be essential to
elucidate the role of this variation in the etiology of nephrolithiasis.
The CLDN14 gene was shown to be associated with nephro-
lithiasis in the previous GWAS in Caucasian [8], but SNPs
rs219778 and rs219781 did not exhibit significant association
(P=0.937 and 0.630, respectively), while SNP rs219780 was not
polymorphic in Japanese. However SNP rs2835349 which is
located at 19 kb upstream of the CLDN14 gene was included in the
top 100 SNPs in our GWAS (P=6.33610
25 with OR of 1.22,
Figure S9). SNP rs2835349 did not achieve the threshold of the
first replication analysis (P,8.47610
24) but revealed some trend
of the association with P-value of 3.29610
23 and OR of 1.10
(Table S9). To further investigate the association of this variation
with nephrolithiasis, we genotyped rs2835349 using stage 3 cohort.
Although rs2835349 failed to show the replication of association
with P-value of 0.624 and OR of 0.98 (95% C.I. of 0.94–1.10),
metanalysis of three studied indicated the suggestive association
(P=5.72610
24 and OR of 1.10). Taken together, CLDN14 would
be a common genetic locus for nephrolithiasis in both Caucasian
and Japanese populations.
Then we conducted the multiple logistic regression analysis
of three significant variations (rs11746443, rs1000597, and
rs4142110) including age, gender, and BMI as covariates. As a
result, these variations remained as factors that were strongly
associated with nephrolithiasis with OR of 1.18 (95% confidence
interval (C.I.) of 1.12–1.25), 1.21 (95% C.I. of 1.14–1.27), and 1.14
(95% C.I. of 1.09–1.19), respectively (Table S10), indicating these
Table 1. Summary of GWAS and replication analyses.
SNP stage allele gene
Case
MAF
a
Control
MAF
a P
b OR
c 95%CI
c Phet
e
rs12654812 GWAS a/g RGS14-SLC34A1-PFN3-F12
(5q35.3)
0.397 0.346 1.98610
25 1.24 1.13–1.37
Stage2 0.381 0.354 5.57610
24 1.13 1.05–1.20
Stage3/Replication 0.386 0.35 5.27610
25 1.17 1.08–1.26
Combined
d 4.42610
211 1.16 1.11–1.22 0.267
rs11746443 GWAS t/c RGS14-SLC34A1-PFN3-F12
(5q35.3)
0.29 0.244 1.62610
25 1.27 1.14–1.41
Stage2 0.283 0.252 1.93610
25 1.17 1.09–1.26
Stage3/Replication 0.278 0.25 4.64610
24 1.16 1.07–1.26
Combined
d 8.51610
212 1.19 1.13–1.24 0.378
rs12669187 GWAS t/c INMT-FAM188B-AQP1
(7p14.3)
0.223 0.176 1.04610
26 1.34 1.19–1.51
Stage2 0.214 0.184 4.56610
26 1.21 1.11–1.31
Stage3/Replication 0.205 0.182 1.59610
23 1.16 1.06–1.27
Combined
d 1.48610
212 1.22 1.15–1.28 0.157
rs1000597 GWAS g/a INMT-FAM188B-AQP1
(7p14.3)
0.246 0.202 1.06610
25 1.29 1.15–1.45
Stage2 0.241 0.204 4.60610
28 1.24 1.15–1.34
Stage3/Replication 0.23 0.203 5.43610
24 1.17 1.07–1.28
Combined
d 2.16610
214 1.22 1.16–1.29 0.37
rs4142110 GWAS a/g DGKH
(13q14.1)
0.41 0.46 7.15610
25 1.22 1.11–1.35
Stage2 0.43 0.458 7.03610
24 1.12 1.05–1.19
Stage3/Replication 0.431 0.459 2.18610
23 1.12 1.04–1.20
Combined
d 4.62610
29 1.14 1.09–1.19 0.301
5,796 (904 in GWAS, 2,783 in stage2 and 2,109 in stage 3/replication) Nephrolithiasis cases and 17,344 (7,471 in GWAS and 5,251 in stage2 and 4,622 in stage3/
replication) controls were analyzed.
aMAF: minor allele frequency.
bP value obtained from Cochrane-Armitage trend test.
cOdds ratios (OR) and confidence interval (CI) are calculated using the non-susceptible allele as reference.
dCombined: Odds ratio and P value for independence test were calculated by Mendel-hauzen and Laird method in the Meta-analysis.
eThe P values of heterogeneities (Phet) across three stages examined by using the Breslow-Day test.
doi:10.1371/journal.pgen.1002541.t001
GWAS of Nephrolithiasis Identifies Three Novel Loci
PLoS Genetics | www.plosgenetics.org 3 March 2012 | Volume 8 | Issue 3 | e1002541SNPs as an independent risk factors. Therefore, we examined
cumulative effect of these variations using weighted genetic risk
score (wGRS) as describe previously [20]. We defined 4 categories
by using the mean and SD of control samples (Group 1: less than
21S.D. (,0.127), Group 2: between 21S.D. and mean (0.127–
0.309), Group 3 between mean and +1S.D. (0.309–0.490), Group
4: more than +1S.D. (0.490,)). As a result, we found that
individuals in Group 4 have 1.95-fold higher risk of nephrolithiasis
than those in Group 1 (Table S11a, S11b). These results indicated
the cumulative effect of these variations.
Through the GWAS and two sets of replication studies using a
total of 5,892 cases and 17,809 controls, we identified three
significantly-associated loci for nephrolithiasis. Although the
molecular mechanisms how these variations could increase the
risk of nephrolithiasis should be further investigated, our results
elucidated crucial roles of genetic factors related with renal
function as well as pathogenesis of nephrolithiasis. Nephrolithiasis
is considered as one of lifestyle-related diseases; low fluid
intake, low dietary calcium, and high dietary salt have been
shown to increase the disease risk. However the results of dietary
intervention studies to reduce the recurrence incidence of neph-
rolithiasis has been unsuccessful [21]. We think that our findings
would contribute to the better understanding of pathogenesis of
nephrolithiasis and lead to the development of new innovative
therapeutics.
Materials and Methods
Ethics statement
All subjects provided written informed consent. This project was
approved by the ethical committees at the Institute of Medical
Science, University of Tokyo, and Center for Genomic Medicine,
Institutes of Physical and Chemical Research (RIKEN).
Samples
Characteristics of each cohort are shown in Table S1. In
this study, we conducted GWAS and two subsequent replication
analyses using a total of 5,892 nephrolithiasis cases and 17,809
control subjects. All case samples and 16786 of non-nephrolithiasis
case-mix control subjects were obtained from BioBank Japan
project, ‘‘the Leading Project for Personalized Medicine’’ in the
Ministry of Education, Culture, Sports, Science and Technology
[22]. We excluded patients with struvite, cystine, ammonium acid
urate, and uric acid stone. Patients with secondary nephrolithiasis
caused by drugs, hyperparathyroidism, or congenital anomalies of
urinary tract were also excluded. We excluded the subjects with a
history of diabetes, hypertension, and dyslipidemia from controls,
because these diseases were shown to be a risk factor for nephro-
lithiasis [23]. We also obtained 1023 Japanese control DNAs from
healthy volunteers from the Osaka-Midosuji Rotary Club, Osaka,
Japan. A total of 27,323 Japanese samples from Biobank Japan
were used for the QTL analyses of serums calcium, phosphorus,
urate, BMI and eGFR.
SNP genotyping
Genomic DNA was extracted from peripheral blood leukocytes
using a standard method. In the GWAS, a total of 1000 cases and
7,936 non-nephrolithiasis controls (cerebral aneurysm, primary
sclerosing cholangitis, esophageal cancer, uterine body cancer
chronic obstructive pulmonary, glaucoma, and healthy volunteers)
were genotyped at 712,726 SNPs using Human Omni Express
(Figure S1). We performed a standard quality control procedure
to exclude SNPs with low call rate (,99%), P-value of Hardy-
Weinberg equilibrium test of ,1.0610
26 in controls, and minor
allele frequency (MAF) of ,0.01 in each stage. Finally, we
analyzed 556,249 SNPs in GWAS. In stage2, we genotyped 2,783
cases and 5,251 non-nephrolithiasis controls (epilepsy, atopic
dermatitis, and Grave’s disease) by using multiplex PCR-based
Invader assay (Third Wave Technologies) or Human Omni
Express, respectively. In replication/stage 3, we genotyped 2,109
cases and 4,622 non-nephrolithiasis controls (chronic hepatitis
C, liver cancer, and colon cancer) using multiplex PCR-based
Invader assay (Third Wave Technologies). For the QTL analyses,
we genotyped 27,323 samples using Illumina HumanHap610-
Quad Genotyping BeadChip as described previously [24].
Statistical analysis
The association of SNPs with nephrolithiasis in each stage
was tested by a 1-degree-of-freedom Cochran-Armitage trend test
using PLINK [25]. The genomic inflation factor l was calculated
using all the tested SNPs in the GWAS. The quantile-quantile plot
was drawn using R program. The Odds ratios were calculated
using the non-susceptible allele as reference, unless it was stated
otherwise elsewhere. The combined analysis of GWAS and the
replication stages was performed utilizing the Mantel-Haenszel
method. In this study, we set genome wide significance threshold
of 5610
28 in meta-analysis of all stages [26,27]. We also assumed
a significant level of 7.85610
25 (TOP 100 SNPs) in GWAS,
8.47610
24 (0.05/59) in stage2, and 5.00610
23 (0.05/10) in stage
3, respectively. We selected SNPs which satisfied all these four
Table 2. QTL analysis for serum phosphorus, serum calcium,
serum urate, eGFR, and BMI.
Traits SNP MAF beta s.e.
a P
b
Serum phosphorus
rs11746443 0.233 20.074 0.35 8.32610
21
rs1000597 0.212 0.401 0.34 2.33610
21
rs4142110 0.435 20.49 0.28 8.01610
22
Serum calcium
rs11746443 0.233 0.00049 0.019 9.80610
21
rs1000597 0.204 20.0019 0.019 3.24610
21
rs4142110 0.464 0.025 0.016 1.11610
21
Serum urate
rs11746443 0.231 20.0032 0.02 8.75610
21
rs1000597 0.214 0.012 0.02 5.72610
21
rs4142110 0.344 20.0067 0.016 6.81610
21
estimated glomerular filtration rate (eGFR)
rs11746443 0.23 21.85 0.34 6.54610
28
rs1000597 0.211 0.176 0.33 5.97610
21
rs4142110 0.461 0.33 0.27 2.24610
21
Body mass index (BMI)
rs11746443 0.23 0.096 0.04 1.71610
22
rs1000597 0.211 0.074 0.039 5.01610
22
rs4142110 0.461 20.00011 0.032 9.97610
21
QTL analysis for serum level for phosphorus (n=2,085), calcium (n=4,807),
urate (n=16,702), eGFR (n=21,842), and BMI (n=24,406). Estimated GFR (eGFR)
is calculated by formulas using blood test result, age, gender. eGFR (mL/min/
1.73 m
2)=1946serum creatinine (mg per 100 ml)
21.0946age2
0.287 (60.739 if
female).
as.e.=standard error of mean,
bP values were obtained from logistic regression analysis using age, gender,
smoking, alcohol, and BMI (phosphorus, calcium, and urate); smoking, alcohol,
and BMI (eGFR); or age, gender, smoke, and alcohol (BMI) as covariates.
doi:10.1371/journal.pgen.1002541.t002
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using the Breslow-Day test [28]. The statistical power is 31.6%
in GWAS (P=7.85610
25), 96.38% in stage2 (P=0.05/59),
95.54% in stage3 (P=0.05/10), and 99.37% in all stage
(P=5.00610
28) at minor allele frequency of 0.3 and Odd ratio
of 1.2. For multiple logistic regression analysis at rs11746443,
rs1000597 and rs4142110, we considered age at recruitment,
gender, and BMI as covariates using the R program.
Imputation analysis
We used a Hidden Markov model programmed in MACH [29]
and haplotype information from HapMap JPT samples to infer the
genotypes of untyped SNPs in the GWAS. We applied the same
SNP quality criteria as in GWAS for selecting SNPs for the
analysis. The association was tested by 1-degree-of-freedom
Cochran-Armitage trend test.
Serum calcium, phosphorus, urate, BMI, and a kidney
functional index of eGFR analysis
We assessed the effect of genetic variations on serum calcium,
phosphorus, urate, BMI, and eGFR, as described previously [30].
In brief, we used the genotyping result from 27,323 Japanese
individuals with various diseases those were genotyped by using
the Illumina Human610-Quad BeadChip. Since three significant
SNPs (rs11746443, rs1000597, and rs4142110) were not included
in Illumina Human610-Quad BeadChip, genotype data of these
SNPs were determined by imputation using the MACH software.
We compared the data from imputation analysis and that form
direct sequencing for SNPs rs11746443, rs1000597 and rs4142110
using 94 samples. The concordance rates were 100% for
rs1000597 and rs4142110 and 97.7% for rs11746443. All the
samples were obtained from Biobank Japan. For serum calcium,
phosphorus and urate, a linear regression model was used to
analyze the associations of quantitative traits with SNP genotypes
by incorporating age, gender, alcohol, smoking status, and BMI as
covariates. For BMI, a linear regression model was used to analyze
the associations of quantitative traits with SNP genotypes by
incorporating age, gender, alcohol, smoking status as covariates.
GFR was estimated using the following formula [31]: eGFR (mL/
min/1.73 m
2)=1946serum creatinine (mg per 100 ml)
21.0946
age2
0.287 (60.739 if female). For eGFR, a linear regression model
was used to analyze the associations of quantitative traits with SNP
genotypes by incorporating alcohol, smoking status, as covariates.
Quantitative real-time PCR
mRNA or total RNA from normal tissues were purchased from
Calbiochem and BioChain. cDNAs were synthesized with the
SuperScript Preamplification System (Invitrogen). Quantitative
real-time PCR was conducted using the SYBR Green I Master on
a LightCycler 480 (Roche). The primer sequences are indicated
in Table S12. ENST00000434909 cDNA was amplified with a
primer pair encompassing the region containing from exon 5 to
exon7. Gene structure of ENST00000434909 was confirmed by
direct sequencing of PCR product.
The weighted Genetic Risk Score (wGRS)
The wGRS was calculated by multiplying the number of risk
alleles for each SNP by weight for that SNP (the natural log of the
odds ratio for each allele) (Table S11a), and then taking the sum
across the 3 SNPs according to the following formula:
wGRS~
X 3
i~1
wi Xi
Where i is the SNP, wi is the weight for SNPi, and Xi is the
number of risk alleles (0, 1 or 2).
Software
For general statistical analysis, we employed R statistical
environment version 2.9.1 (cran.r-project.org) or plink-1.06
(pngu.mgh.harvard.edu/,purcell/plink/). The Haploview soft-
ware version 4.2 [32] was used to calculate LD and to draw
Manhattan plot.Primer3 -web v0.3.0(http://frodo.wi.mit.edu) web
Figure 1. Regional association plots at rs11746443, rs1000597, and rs4142110 loci. (a–c) Upper panel; P-values of genotyped SNPs (circle)
and imputed SNPs (cross) are plotted (as 2log10 P-value) against their physical position on chromosome 5 (a), 7 (b), and 13(c) (NCBI Build 36). SNPs
rs11746443 on 5q35 (a), rs1000597 on 7p14 (b), and rs4142110 on 13q14 (c) are represented by purple diamonds. The genetic recombination rates
estimated from 1000 Genomes samples (JPT+CHB) are shown with a blue line. SNP’s color indicates LD with rs11746443 (a), rs1000597 (b), and
rs4142110 (c) according to a scale from r
2=0tor
2=1 based on pair-wise r
2 values from HapMap JPT. Middle Panel; Gene annotations from the
University of California Santa Cruz genome browser. Lower Panel; We drew the LD map based on D’ values using the genotype data of the cases and
controls in the GWAS samples.
doi:10.1371/journal.pgen.1002541.g001
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csg.sph.umich.edu/locuszoom/) for plotting regional association
plots. We used SNP Functional Prediction [33] web tool for
functional annotation of SNPs (http://snpinfo.niehs.nih.gov/
snpfunc.htm). We used MACTH [34] web tool for searching
potential binding sites for transcription factors (http://www.gene-
regulation.com/index.htm).
Supporting Information
Figure S1 Summary of study design and results.
(TIF)
Figure S2 Principal Component Analysis (PCA) plots showing
the distribution of case and control used in the GWAS. CEU;
Utah residents with Northern and Western European ancestry
from the CEPH collection. YRI; Yoruban in Ibadan, Nigeria.
CHB; Han Chinese in Beijing, China. JPT; Japanese in Tokyo,
Japan. Case and control samples belonged to Hondo cluster
according to PCA were used in this study.
(TIF)
Figure S3 Association analysis using all samples included in
Hondo and Ryukyu clusters. Quantile-quantile plots for test
statistics (Cochran-Armitage trend test) for 556,249 SNPs passing
the quality control. Black dots are the uncorrected test statistics
(l=1.123). Under the null hypothesis of no association at any loci,
the points would be expected to follow the red line (y=x).
(TIF)
Figure S4 a) Association analysis using all samples. Quantile-
quantile plots for test statistics (logistic regression analysis using top
principle components as covariate) for 556,249 SNPs passing the
quality control. Black dots are the uncorrected test statistics
(l=1.054). Under the null hypothesis of no association at any loci,
the points would be expected to follow the red line (y=x). b,
Association analysis using samples included in a Hondo cluster.
Quantile-quantile plots for test statistics (Cochran-Armitage trend
test) for 556,249 SNPs passing the quality control. Black dots are
the uncorrected test statistics (l=1.042). Under the null
hypothesis of no association at any loci, the points would be
expected to follow the red line (y=x). c, Association analysis using
samples included in a Hondo cluster. Manhattan plot showing the
genome-wide P values of association. The P values were calculated
by Cochran-Armitage trend test. The y axis represents the 2log10
P values of 556,249 SNPs, and x axis shows their chromosomal
positions. The horizontal blue line shows the threshold of
P#7.85610
25 for selecting top 100 SNPs for replication.
(PDF)
Figure S5 Forest plots for stratified association analysis at
rs11746443 (a), rs1000597 (b) and rs4142110 (c). Case and control
samples from GWAS, replication1, and replication 2 were stratified
by age (case; $60 n=2006 ,60 n=3689, control; $60 n=8300
,60 n=8837), gender (case; male n=4268 female n=1434,
control; male n=9462 female n=7863), and BMI (case; $24
n=2592 ,24 n=2656, control; $24 n=4781 ,24 n=10586).
Odds ratios and confidence intervals are calculated from fixed effect
model implemented in R. The P values of heterogeneities (Phet)
across three stages examined by using the Breslow-Day test.
(PDF)
Figure S6 Enlarged regional plots of three significant susceptibility
loci at 5q35, 7p14, and 13q14. (a–c) Upper panel; P values of
genotyped SNPs (circle) and imputed SNPs (cross) are plotted (as
2log10 P value) against their physical position on chromosome 5 (a),
7 (b), and 13(c) (NCBI Build 36). SNPs rs11746443 on 5q35 (a),
rs1000597 on 7p14 (b), and rs4142110 on 13q14 (c) are represented
by purple diamonds. The genetic recombination rates estimated
from1000Genomessamples(JPT+CHB)areshownwithablueline.
SNP’s color indicates LD with rs11746443 (a), rs1000597 (b), and
rs4142110 (c) according to a scale from r
2=0tor
2=1 based on pair-
wise r
2 values from HapMap JPT. Middle Panel; Gene annotations
from the University of California Santa Cruz genome browser.
Lower Panel; We drew the LD map based on D’ values using the
genotype data of the cases and controls in the GWAS samples.
(PDF)
Figure S7 Expression of SLC34A1, AQP1 and DGKH genes in 27
normal tissues. Quantitative PCR analysis of SLC34A1 (a), AQP1
(b), and DGKH (c) in normal tissues. ACTB was used for
normalization of expression levels.
(TIF)
Figure S8 Expression of ENST00000434909. (a) Gene Structure of
FAM188B, AQP1 and ENST00000434909. Locations of rs12669187
and rs1000597 are intronic 4 and intronic 6 of ENST00000434909.( b )
Protein structure of AQP1, FAM188B, and ENST00000434909. (c)
Quantitative PCR analysis of ENST00000434909 in normal tissues.
ACTB was used for normalization of expression levels.
(TIF)
Figure S9 Regional association plots at rs2835349 loci. Upper
panel; P-values of genotyped SNPs (circle) and imputed SNPs (cross)
are plotted (as 2log10 P-value) against their physical position on
chromosome 21 (NCBI Build 36). SNPs rs2835349 on 21q22 are
represented by purple diamonds. The genetic recombination rates
estimated from 1000 Genomes samples (JPT+CHB) are shown with
a blue line. SNP’s color indicates LD with rs2835349 according to a
scalefrom r
2=0tor
2=1 based onpair-wiser
2 valuesfromHapMap
JPT. Middle Panel; Gene annotations from the University of
California Santa Cruz genome browser. Lower Panel; We drew the
LD map based on D’ valuesusing the genotype data of the cases and
controls in the GWAS samples.
(TIF)
Table S1 Characteristics of samples and methods used in this
study.
(DOCX)
Table S2 The Result of GWAS for nephrolithiasis (Top 100
SNPs).
(DOCX)
Table S3 Results of association analysis for nephrolithiasis in
stage2 (59 SNPs).
(DOCX)
Table S4 Results of meta-analysis between GWAS and Stage 2
for nephrolithiasis (59 SNPs).
(DOCX)
Table S5 a) Results of association analysis for nephrolithiasis in
stage3/replication (11 SNPs). b) Results of meta analysis of 3 stage
(11SNPs).
(DOCX)
Table S6 The results of conditional analysis for significantly SNPs
in 5q35.3 or 7p14.3 associated with nephrolithiasis in all stages.
(DOCX)
Table S7 Result of imputation analysis at 5q35.3.
(DOCX)
Table S8 Result of imputation analysis and snp location at
7p14.3 (a) and 13q14.1 (b).
(DOCX)
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stage and combined analysis.
(DOCX)
Table S10 Multiple logistic regression analysis for risk of
nephrolithiasis.
(DOCX)
Table S11 a) SNPs that compose the weighted genetic risk score
and weights assigned to each marker. b) wGRS scores and odd
ratios of nephrolithiasis by wGRS groups.
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